AZTR
Azitra, Inc.0.3001
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
3.22MP/E (TTM)
-Basic EPS (TTM)
-1.47Dividend Yield
0%Recent Filings
8-K
Azitra closes $10.5M PIPE
Azitra closed a PIPE financing on March 20, 2026, issuing 10,485 shares of Series A preferred stock at $1,000 each for $10.5 million initial proceeds, plus Series B and C warrants for 85 million common shares at $0.123 exercise price; full exercise could yield $31.4 million. Preferred converts post-stockholder approval into ~8,128 common shares each, funding R&D and operations. Warrants hinge on approval; Series C ties to filaggrin study data.
8-K
NYSE non-compliance notice
Azitra received NYSE American notice on March 13, 2026, for failing Section 1003(a)(iii) stockholders' equity rule, with $3.8M as of December 31, 2025—below the $6.0M threshold amid five years of losses. Its prior compliance plan, accepted December 16, 2025, now covers both rules through April 1, 2027. Trading continues. Delisting looms if unmet.
8-K
Special meeting canceled
10-K
FY2025 results
Azitra posted FY2025 results reflecting its early-stage clinical biopharma status with no revenue and ongoing operating losses, as anticipated for a precision dermatology developer. Q4 saw dosing of first ATR-04 patients in a Phase 1/2 trial for EGFRi rash after FDA Fast Track nod, building on ATR-12's Phase 1b safety data from H1 2025 and first Netherton patient dosed in August 2024. No quarterly financials disclosed in the 10-K. Pipeline advanced steadily. Cash burn continues. Clinical trials may fail to show efficacy.
8-K
Azitra's 2025 loss widens
Azitra reported $11.0 million net loss for 2025, up from $9.0 million in 2024, with R&D steady at $4.8 million and cash down to $2.1 million. Pipeline advanced: ATR-04 Phase 1/2 trial dosed first patient for EGFRi rash; ATR-12 Phase 1b showed promising safety in Netherton syndrome. Topline data expected mid- to H2 2026. Funding secured $8.5 million.
ARQT
Arcutis Biotherapeutics, Inc.
28.53-0.42
ATOS
Atossa Therapeutics, Inc.
0.72+0.01
ATRA
Atara Biotherapeutics, Inc.
17.58-0.37
ATXS
Astria Therapeutics, Inc.
12.87-0.05
ATYR
aTyr Pharma, Inc.
0.73-0.00
BFRI
Biofrontera Inc.
0.73-0.06
BLRX
BioLineRx Ltd.
3.01-0.17
DRMA
Dermata Therapeutics, Inc.
2.32-0.16
GRTX
Galera Therapeutics, Inc.
0.02+0.00
SPRY
ARS Pharmaceuticals, Inc.
10.66+0.07